Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

One third of patients who stop treatment for schizophrenia early do so due to poor response

23.12.2005


A third of patients treated for schizophrenia who stop taking their medication early do so because they do not feel any significant improvement or because their symptoms are worsening. A study published today in the open access journal BMC Medicine reveals that patients with schizophrenia are three times more likely to stop treatment because of poor response or worsening symptoms, than because of adverse non-psychiatric side effects.



Hong Liu-Seifert and colleagues from Eli Lilly and Company in Indianapolis, USA, analysed the reasons for stopping treatment of patients who took part in four previous Eli Lilly studies. The studies included a total of 1627 patients and compared the effects of taking olanzapine, risperidone, quetiapine or ziprasidone in patients diagnosed with schizophrenia or related disorders.

Liu-Seifert et al.’s analysis shows that 53% (866/1627) of patients stopped treatment early. Of the 866 patients who stopped treatment, 36% (315/866) did so because the treatment was felt not to be effective or because their symptoms worsened. Only 12% of patients who stopped treatment early did so because of adverse events such as dizziness, fatigue, vomiting or weight gain.


Of the 315 patients who stopped because of poor response to treatment, 80% stopped because they themselves believed it wasn’t effective. Only 20% of the patients studied stopped taking medication based on a doctor’s decision that the treatment wasn’t effective.

"Discontinuation due to patient perception of poor response appeared to occur particularly early in the course of treatment," the authors write. Liu-Seifert et al. found that patients who experienced an early response to medication were 80% more likely to complete treatment.

The authors’ findings suggest that early and effective symptom control, and discussing expectations of treatment, may help to ensure that people suffering from schizophrenia continue to take their medication.

Juliette Savin | alfa
Further information:
http://www.biomedcentral.com

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>